TMS Electrochemotherapy for Glioblastoma Multiforme
Primary Purpose
Glioblastoma
Status
Withdrawn
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
TMS
Sponsored by
About this trial
This is an interventional treatment trial for Glioblastoma
Eligibility Criteria
Inclusion Criteria:
- Newly diagnosed and histologically confirmed glioblastoma multiform
- MGMT gene methylation
- If age < 70, eligibility to comply with the Stupp radio chemotherapy regimen
- If age > 70, eligibility for stand alone chemotherapeutic treatment
- Ability to comply with the proposed TMS treatment
- Use of validated anti-conception for fertile female participants in concordance with guidelines provided by the Danish Health and Medicines Authority
Exclusion Criteria:
- Pregnancy or nursing
- Other conditions that may contraindicate the use of transcranial magnetic stimulation
- Implanted pacemaker or metal contraindicating MRI-scan
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
TMS electrochemotherapy
Arm Description
Combined TMS (transcranial magnetic stimulation) and Temozolomide chemotherapy.
Outcomes
Primary Outcome Measures
Time to death
Time from onset primary diagnosis until death
Secondary Outcome Measures
Time to progression
Time from diagnosis until radiological tumor progression
Quality of Life
Full Information
NCT ID
NCT02283944
First Posted
November 3, 2014
Last Updated
September 13, 2021
Sponsor
University of Aarhus
1. Study Identification
Unique Protocol Identification Number
NCT02283944
Brief Title
TMS Electrochemotherapy for Glioblastoma Multiforme
Official Title
TMS Electrochemotherapy for Glioblastoma Multiforme
Study Type
Interventional
2. Study Status
Record Verification Date
October 2014
Overall Recruitment Status
Withdrawn
Why Stopped
Device for multi coil TMS no longer supported
Study Start Date
January 2015 (undefined)
Primary Completion Date
January 2018 (Anticipated)
Study Completion Date
May 31, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Aarhus
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The proposed project aims to develop novel electrochemotherapeutic treatment of glioblastoma multiforme (GBM). Standard treatment has limited effect on survival and quality of life. Electrochemotherapy is a novel and promising treatment, which has demonstrated convincing results in the treatment of various types of carcinoma. The treatment is based on a combination of electrical current stimulation of tumor cells and simultaneous administration of chemotherapeutic drugs. Electrochemotherapy works by inducing an electrical current between implanted electrodes in the tumor tissue, causing electroporation of the cancer cell membranes, and thereby increasing the cellular permeability and drug uptake. Electrochemotherapy has proven to be an efficient way of considerably increasing the potency of the chemotherapeutic drug bleomycin in malignant cells in skin tumors and carcinoma metastases, and thereby increasing cytotoxicity of the drug locally in the tumor tissue. This allows for treatment with lower doses of chemotherapeutic drugs and more defined, local area of effect, thus decreasing systemic effects. The investigators propose to use a novel non-invasive and safe technique called focused transcranial magnetic stimulation (focused TMS) to induce electrical current in the tumor tissue. TMS is a safe and widely implemented technology used to treat multiple neurological diseases such as pain, depression and stroke. Studies have shown that effective electroporation of cell membranes can be obtained using induction of electromagnetic fields in a cell suspension, and new focused TMS further enables focused treatment of selected brain regions without surgical intervention and, thereby focusing chemotherapeutic treatment to pathological tissue and avoiding surgery related brain tissue damage. Additionally, TMS transiently increases blood-brain barrier permeability, theoretically allowing increased uptake of chemotherapeutic drugs in the target area. This addresses a significant challenge in the treatment of brain cancer, as most cytotoxic drugs have fairly limited ability to pass the blood brain barrier.
The intention of this research project is to investigate the therapeutic potential of focused TMS as an alternative non-invasive source of current induction and thereby means to treat several types of brain cancer with electrochemotherapy.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Glioblastoma
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
TMS electrochemotherapy
Arm Type
Experimental
Arm Description
Combined TMS (transcranial magnetic stimulation) and Temozolomide chemotherapy.
Intervention Type
Device
Intervention Name(s)
TMS
Other Intervention Name(s)
Transcranial Magnetic Stimulation
Intervention Description
Pulsed non-invasive brain stimulation using electromagnets
Primary Outcome Measure Information:
Title
Time to death
Description
Time from onset primary diagnosis until death
Time Frame
3 years
Secondary Outcome Measure Information:
Title
Time to progression
Description
Time from diagnosis until radiological tumor progression
Time Frame
3 years
Title
Quality of Life
Time Frame
3 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Newly diagnosed and histologically confirmed glioblastoma multiform
MGMT gene methylation
If age < 70, eligibility to comply with the Stupp radio chemotherapy regimen
If age > 70, eligibility for stand alone chemotherapeutic treatment
Ability to comply with the proposed TMS treatment
Use of validated anti-conception for fertile female participants in concordance with guidelines provided by the Danish Health and Medicines Authority
Exclusion Criteria:
Pregnancy or nursing
Other conditions that may contraindicate the use of transcranial magnetic stimulation
Implanted pacemaker or metal contraindicating MRI-scan
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anders R Korshøj, MD
Organizational Affiliation
Aarhus University Hospital, Department of Neurosurgery
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
TMS Electrochemotherapy for Glioblastoma Multiforme
We'll reach out to this number within 24 hrs